Why it's time to wake up to ResMed Inc.'s (CHESS) potential

ResMed Inc. (CHESS) (ASX:RMD) remains one of the ASX's best healthcare businesses.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Global sleep treatment business ResMed Inc. (CHESS) (ASX: RMD) this morning posted another solid quarter of operations for the quarter ending December 31 2016, with adjusted net profit up 1% to US$103.3 million and adjusted earnings per share flat at US73 cents per share. This compares to analysts' reported estimates of US70 cents per share. The company also faced some currency headwinds over the quarter due to the weaker Euro and stronger Australian dollar.

Compared to the prior corresponding quarter the result is distorted by the US$800 million acquisition of the Brightree Inc. health software business in April 2016, although excluding the contribution from the Brightree business revenue for the quarter was up 9% to US$496.6 million.

The highlights for the quarter were strong revenue growth in its core North America market and another promising quarter in its developing China market that is part of ResMed's Curative Medical business that is growing quickly in a vast market.

Despite the strong revenue growth the net profit for the quarter was generally flat due to rising administrative and research expenses, with adjusted gross margins of 58.3% marginally down on the prior quarter's adjusted gross margins of 58.9%.

Overall, on a quarter-on-quarter basis that includes the effects of the Brightree Inc acquisition the company appears to have grown adjusted income from operations quite strongly at US$131.6 million versus US$111 million in the prior quarter. This success partly attributed to the strong performance of the Brightree business.

Positioning for the future

In the sleep treatment medical device space it's vital to invest for the future to ensure you have market-leading products to command price premiums, with more strong device sales growth likely to carry on thanks to its AirSense 10 platform that is now supported by cloud-connected technology.

On technology milestones reached for the quarter the company's chief executive officer, Mick Farrell, commented: "We continue to pioneer game-changing products and create value with our solutions. This quarter we announced: FDA clearance for the world's smallest travel CPAP; the creation of SleepScore Labs to focus on consumer sleep wellness; reaching the milestone of one billion nights of sleep data; and new research demonstrating that the use of myAir™ significantly improves patient adherence to sleep therapy in Europe."

It's the company's long-term focus that is one of its most attractive qualities as it embraces the move into digital health care solutions that leads to competitive advantages and bulletproof like revenue growth.

Over time I expect the tech-driven, cloud connected, software-as-a-service nature of the business will lead to rising margins, which mixed with double-digit revenue growth are likely to trigger analyst upgrades and decent share price gains over the medium term.

Dividends and currency exposures

A US33 cent per share quarterly dividend was declared which will equate to an FX-adjusted US3.3 cents per chess depositary instrument (CDI) held by Australian investors who own the CDIs traded on the ASX. Australian investors in ResMed are beneficiaries of a stronger US dollar as each CDI represents a one tenth interest in the company's scrip traded on the New York Stock Exchange.

This is important to note as the ASX scrip will follow the AUD / USD spot rate closely. The primary US scrip currently sells for US$63.60, so for example if the AUD plunged to only buy US63.6 cents tomorrow the CDIs would be worth around A$10 tomorrow, compared to A$8.32 today.

For Australian investors then it's better to buy this stock when the AUD / USD spot rate is stronger as this provides a greater currency related margin of safety. Today the Australian dollar buys US75.6 cents which I expect is marginally above where it will trade over the rest of the year, however if you do expect the US dollar to significantly appreciate over the year ahead now would be a good time to buy the ASX scrip.

If you annualise earnings per share to US$2.92 per share the US scrip trades on around 22x annualised earnings at US$63.60, which looks ok value compared to other healthcare leaders like CSL Limited (ASX: CSL) or Cochlear Limited (ASX: COH), that command higher multiples, but are growing profits at stronger rates.

ResMed again forecast that it intends to return to its share buyback program in fiscal year 2018 after cancelling it this year due to the need to fund the Brightree acquisition. It remains one of the better options on the ASX for long-term focused investors and under $8.40 the stock looks a buy today.

Motley Fool contributor Tom Richardson owns shares of ResMed Inc., Cochlear and CSL Limited. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »